2016
In silico fragment-based hit identification for efficient discovery of new cosmetic ingredient
RICT 2016
Smart chemical libraries from Prestwick Chemical: powerful tools for high-quality hit discovery
Med. Chem. Commun. 2016, 7, 506-511
Fragment pharmacophore-based in silico screening: a powerful approach for efficient lead discovery
2015
BSI Summer School 2015
CD41 (Itga2b) identifies lymph node lymphatic endothelial cells activated by RANKL
SLAS 2015
The Prestwick Chemical Library®, a valuable tool for screening
WO 2015191799
Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof
WO 2015103489
Heteroatom containing deoxyuridine triphosphatase inhibitors
2014
EFMC-ISMC 2014
Structure-based discovery of novel NIK inhibitors
EFMC-ISMC 2014
Comparison of hit discovery approaches. Case study: NIK inhibitors
EFMC-ISMC 2014
Pharmacophore-based characterization of the Prestwick Chemical Library®
EFMC-ISMC 2014
High throughput behevioral sleep assay for larval zebrafish
SfN 2014
In vivo characterization of a novel highly potent GPR88 agonist
SLAS 2014
Screening for neuroprotective activity in a Drosophila model of Parkinson’s disease using a new Prestwick Drosophila library
WO 2014107622
Deoxyuridine triphosphatase inhibitors
WO 2014019023
Alpha7 nicotinic acetylcholine receptor modulators and uses thereof
US 20140088108
2-(3-Aminoaryl) amino-4-aryl-thiazoles and their use as c-Kit inhibitors
2013
Anal. Chem. 2013, 85(18), 8787-8795
Chemical library screening using a SPR-Based inhibition in solution assay: simulations and experimental validation
ANS 2013
BNC375, A novel positive allosteric modulator of the α7 nicotinic acetylcholine receptor, exhibits cognitive enhancement in rodent behavioural models
WO 2013174930
7-Oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO 2013057251
Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO 2013057253
Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO 2013174931
7-Oxo-4,7 -dihydro- pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
2012
WO 2012103583
Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof
2011
Eur. J. Org. Chem. 2011, 32, 6409-6412
Expeditious route towards (+/-)-desethyleburnamonine, a precursor of (+/-) Vindeburnol
WO 2011051478
Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
WO 2011073165
New phenylhydrazone derivatives and their use as pharmaceuticals
2010
WO 2010128163
Small molecule inhibitors of influenza A and B virus and respiratory syncytial virus replication
WO 2010128163
9-Substituted-β-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
WO 2010128163
Styrylquinolines, their process of preparation and their therapeutic uses
WO 2010128163
Styrylquinolines, their process of preparation and their therapeutic uses
WO 2010128163
Styrylquinolines, their process of preparation and their therapeutic uses
US 20100113471
2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
Before 2010
CROI 2009
A new quinoline family of HIV-1 integrase inhibitors acting on HIV-1 mutants selected by integrase strand transfer inhibitors
Rencontres Normandes en CBS 2009
New derivatives of 14,15-dihydro-20,21-dinoreburnamin-14-ol as potent antidepressants
WO 2009106967
Novel 7-substituted derivatives of 3-carboxy-oxadiazino-quinolones, preparation thereof and use thereof as anti-bacterial agents
WO 2008001016
Use of a carbonic anhydrase inhibitor for preparation of a drug for treating skeletal muscle degeneration
WO 2007125246
Use of a tricyclic compound for preparing a medicine for treating skeletal muscle degeneration
Before 2010
WO 2007107545
Cyclic-alkylaminederivatives as inhibitors of the interaction between Mdm2 and p53
WO 2007044796
Pyridazinone compounds as calcilytics
WO 2007045758
6-Heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
WO 2006032631
Inhibitors of the interaction between Mdm2 and p53
WO 2006064375
Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
WO 2006075012
Novel pyrrolodihydroisoquinolines
WO 2006089815
Novel Pyrrolodihydroisoquinolines as PDE10 inhibitors
WO 2006066070
Prodrug constructs of pyrimidone compounds as calcilytics
WO 2005040139
2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
Before 2010
WO 2005073225
2-(3-Substituted-aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors
WO 2005003129
Pyrrolodihydroisoquinolines as PDE10 inhibitors
NWO 2005103047
Derivatives of 14,15-dihydro 20.21-dinoreburnamenin-14-ol, and applications thereof
WO 2005108398
6-Substituted pyridoindolone derivatives production and therapeutic use thereof
WO 2004014903
2-(3-Aminoaryl)amino-4-aryl-thiazoles and their use as c-Kit inhibitors
WO 2004016580
Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid
WO 2004041817
3-Phenyl substituted pyridoindolone, preparation and their therapeutic use thereof
US 7514454
Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
our SOLUTIONS
